GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Response to polyadenosine diphosphate ribose polymerase (PARP) inhibitors in platinum-resistant ovarian cancer and in the absence of BRCA mutations is very low. Combining PARP inhibitors with other agents might overcome this lack of activity. Here we describe the rationale and design of GEICO1601-RO...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Fidalgo, J Alejandro, Iglesias, Maria, Bohn, Uriel, Calvo, Elisa, Garcia, Yolanda, Guerra, Eva, Manso, Luis, Santaballa, Ana, Gonzalez-Martin, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391624/
https://www.ncbi.nlm.nih.gov/pubmed/30820349
http://dx.doi.org/10.4155/fsoa-2018-0107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391624/
https://www.ncbi.nlm.nih.gov/pubmed/30820349
http://dx.doi.org/10.4155/fsoa-2018-0107

Ejemplares similares